Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

copper Cu 64 ucasareotide dasaroxetan

A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional chelator 5-(8-methyl-3,6,10,13,16,19-hexaaza-bicyclo[6.6.6]icosan-1-ylamino)-5-oxopentanoic acid (MeCOSar) and labeled with the positron emission tomography (PET) tracer copper Cu 64, which may be used to image somatostatin receptor (SSTR)-expressing neuroendocrine tumors (NETs) upon PET. Upon administration of copper Cu 64 ucasareotide dasaroxetan, the TATE moiety targets and binds to SSTRs, with high affinity for type 2 SSTR, present on the cell membranes of many types of NETs. This allows for visualization of SSTR-positive tumor cells upon PET. TATE is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and position 8 threoninol is replaced with threonine. SSTRs have been shown to be present in large numbers on NETs and their metastases, while most other normal tissues express low levels of SSTRs.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:64Cu-labeled MeCOSar-Tyr3-octreotate
64Cu-SARTATE
copper 64 SARTATE
copper Cu 64-MeCOSar-Tyr3-octreotate
copper Cu 64-SARTATE
Cu-64 SARTATE
ucasareotide dasaroxetan Cu-64
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search